HC Wainwright & Co. Reiterates Buy on Enliven Therapeutics, Maintains $37 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Enliven Therapeutics, maintaining a price target of $37.
October 01, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Enliven Therapeutics, maintaining a price target of $37, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $37 price target by a reputable analyst firm like HC Wainwright & Co. suggests positive sentiment and confidence in Enliven Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100